PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
16.48 USD
-0.08 (-0.48%)
15.645 USD
-0.84 (-5.07%)
MD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
Each year in the past 5 years MD had a positive operating cash flow.
1.2 Ratios
MD has a better Return On Assets (5.23%) than 80.20% of its industry peers.
Looking at the Return On Equity, with a value of 13.18%, MD belongs to the top of the industry, outperforming 81.19% of the companies in the same industry.
MD's Return On Invested Capital of 9.55% is amongst the best of the industry. MD outperforms 81.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.19%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD's Profit Margin of 5.66% is amongst the best of the industry. MD outperforms 81.19% of its industry peers.
MD has a better Operating Margin (10.97%) than 80.20% of its industry peers.
In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MD has more shares outstanding
Compared to 5 years ago, MD has more shares outstanding
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
MD has an Altman-Z score of 1.97. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.97, MD perfoms like the industry average, outperforming 46.53% of the companies in the same industry.
The Debt to FCF ratio of MD is 2.68, which is a good value as it means it would take MD, 2.68 years of fcf income to pay off all of its debts.
MD has a better Debt to FCF ratio (2.68) than 80.20% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that MD is somewhat dependend on debt financing.
MD has a Debt to Equity ratio (0.70) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 1.97 |
ROIC/WACC1.1
WACC8.68%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Current ratio (1.80) than 67.33% of its industry peers.
MD has a Quick Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a better Quick ratio (1.80) than 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.39%, which is quite impressive.
The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -3.08% in the last year.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.76% yearly.
Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 2.34% on average per year.
EPS Next Y23.94%
EPS Next 2Y12.39%
EPS Next 3Y8.67%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.10, which indicates a very decent valuation of MD.
Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.41.
A Price/Forward Earnings ratio of 8.76 indicates a reasonable valuation of MD.
91.09% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.1 | ||
| Fwd PE | 8.76 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 87.13% of the companies in the same industry.
96.04% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.32 | ||
| EV/EBITDA | 6.64 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y12.39%
EPS Next 3Y8.67%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.48
-0.08 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change1.32%
Ins Owners1.9%
Ins Owner Change8.02%
Market Cap1.44B
Analysts78.75
Price Target16.92 (2.67%)
Short Float %2.26%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)-3.26%
PT rev (3m)-3.26%
EPS NQ rev (1m)-0.68%
EPS NQ rev (3m)5.42%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)10.08%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.1 | ||
| Fwd PE | 8.76 | ||
| P/S | 0.74 | ||
| P/FCF | 6.32 | ||
| P/OCF | 5.87 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.64 |
EPS(TTM)1.81
EY10.98%
EPS(NY)1.88
Fwd EY11.42%
FCF(TTM)2.61
FCFY15.82%
OCF(TTM)2.81
OCFY17.04%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.38
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.97 |
F-Score7
WACC8.68%
ROIC/WACC1.1
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y23.94%
EPS Next 2Y12.39%
EPS Next 3Y8.67%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%